结果显示，ER阴性/PR阴性/HER2阳性(ER-/PR-/HER2+)、单一HR阳性(HR+)/HER2+和三阳性乳腺癌(TPBC)亚型具有不同的临床病理学特征和预后，这一结果提示了需要考虑ER和PR表达对于HER2阳性乳腺癌个体化治疗策略的影响，并强调需要进一步研究来揭示具有不同HR表达模式的HER2阳性乳腺癌的分子特征。
在考虑并排除其他因素(年龄、合并症、群体、种族、诊断年龄、PR、HER2、临床和病理分期等)的影响后,结果显示,豁免辅助内分泌治疗与患者较差的OS结局显著相关(HR=1.25, 95% CI,1.05-1.48, p=0.01),这意味着未接受辅助内分泌治疗的患者死亡风险增加了25%。 图3 豁免辅助内分泌治疗对患者OS的影响 探索性分析:根据...
[7] Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. [8] Yang C, Zhang X, Chen Y,...
1. Tarantino P,Hamilton E, Tolaney S M, et al. HER2-Low Breast Cancer: Pathological andClinical Landscape[J]. Journal of Clinical Oncology, 2020, 38(17): 1951-1962. 2. Clinical and molecular characteristics of HER2-low-...
[2]Zhang LH, Song GH, Shao B, et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis[J]. Anticancer Drugs, 2022, 33(1):e635-e643. doi: 10.1097/CAD...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
[1] Yu KD, Cai YW, Wu SY, et al. Estrogen receptor-low breast cancer: biology chaos and treatment paradox[J]. Cancer Commun (Lond), 2021, 41(10):968-980. doi: 10.1002/cac2.12191 [2] Burstein HJ. Systemic therapy for estrogen recept...
Evaluation of FISH of ER-positive breast cancer with low-HER2 expression could improve their survivaldoi:10.1016/S0959-8049(20)30787-5T. HiguchiF. ArisawaY. HayashiI. ManabeT. SaitoEuropean Journal of Cancer
One study found that the majority of females with a BRCA2 mutation have ER-positive and human epidermal receptor 2 (HER2)-negative BC [4]. Among sporadic BC, ER-positive BC are often characterized by late age of onset, low pathological grade, and low rate of lymph node metastasis and ...
HR 阳性乳腺癌(表达雌激素或孕激素受体,或两者均有)是最常见的乳腺癌亚型,大约70%的乳腺癌肿瘤被认为是HR阳性和HER2-low或阴性。 HR阳性乳腺癌细胞的生长通常由雌激素受体(ER)驱动,针对ER驱动疾病的内分泌疗法被广泛用作晚期疾病的一线治疗,并且通常与细胞周期蛋白依赖性激酶配对(CDK)4/6抑制剂。然而,许多晚期疾...